Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free DMAC Stock Alerts

DiaMedica Therapeutics (DMAC) Competitors

DiaMedica Therapeutics logo
$6.25 +0.20 (+3.31%)
Closing price 04:00 PM Eastern
Extended Trading
$6.25 0.00 (0.00%)
As of 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

DMAC vs. MPLT, CRVS, GHRS, OLMA, and QURE

Should you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Maplight Therapeutics (MPLT), Corvus Pharmaceuticals (CRVS), GH Research (GHRS), Olema Pharmaceuticals (OLMA), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry.

How does DiaMedica Therapeutics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Maplight Therapeutics' return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Maplight TherapeuticsN/A N/A N/A
DiaMedica Therapeutics N/A -77.72%-69.54%

Maplight Therapeutics presently has a consensus price target of $34.43, indicating a potential upside of 23.31%. DiaMedica Therapeutics has a consensus price target of $12.33, indicating a potential upside of 97.33%. Given DiaMedica Therapeutics' higher possible upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Maplight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maplight Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80
DiaMedica Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maplight TherapeuticsN/AN/A-$161.15M-$39.65N/A
DiaMedica TherapeuticsN/AN/A-$32.77M-$0.70N/A

In the previous week, Maplight Therapeutics had 12 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 14 mentions for Maplight Therapeutics and 2 mentions for DiaMedica Therapeutics. Maplight Therapeutics' average media sentiment score of 0.37 beat DiaMedica Therapeutics' score of 0.00 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maplight Therapeutics
5 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
DiaMedica Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Maplight Therapeutics beats DiaMedica Therapeutics on 8 of the 13 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Corvus Pharmaceuticals' return on equity of -23.58% beat DiaMedica Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Corvus PharmaceuticalsN/A -23.58% -20.60%
DiaMedica Therapeutics N/A -77.72%-69.54%

Corvus Pharmaceuticals presently has a consensus price target of $33.33, indicating a potential upside of 112.31%. DiaMedica Therapeutics has a consensus price target of $12.33, indicating a potential upside of 97.33%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Corvus Pharmaceuticals is more favorable than DiaMedica Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corvus Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
DiaMedica Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 28.5% of Corvus Pharmaceuticals shares are owned by insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corvus PharmaceuticalsN/AN/A-$15.28M-$0.50N/A
DiaMedica TherapeuticsN/AN/A-$32.77M-$0.70N/A

In the previous week, Corvus Pharmaceuticals had 2 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 4 mentions for Corvus Pharmaceuticals and 2 mentions for DiaMedica Therapeutics. Corvus Pharmaceuticals' average media sentiment score of 0.50 beat DiaMedica Therapeutics' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corvus Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
DiaMedica Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Corvus Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.

Summary

Corvus Pharmaceuticals beats DiaMedica Therapeutics on 11 of the 13 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to GH Research?

GH Research (NASDAQ:GHRS) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

GH Research's return on equity of -16.30% beat DiaMedica Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
GH ResearchN/A -16.30% -15.77%
DiaMedica Therapeutics N/A -77.72%-69.54%

GH Research is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GH ResearchN/AN/A-$48.26M-$0.80N/A
DiaMedica TherapeuticsN/AN/A-$32.77M-$0.70N/A

In the previous week, GH Research had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for GH Research and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.00 beat GH Research's score of -0.27 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GH Research
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
DiaMedica Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

GH Research has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.

GH Research presently has a consensus price target of $40.13, indicating a potential upside of 88.56%. DiaMedica Therapeutics has a consensus price target of $12.33, indicating a potential upside of 97.33%. Given DiaMedica Therapeutics' higher probable upside, analysts plainly believe DiaMedica Therapeutics is more favorable than GH Research.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GH Research
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73
DiaMedica Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

56.9% of GH Research shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

GH Research beats DiaMedica Therapeutics on 7 of the 13 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Olema Pharmaceuticals?

DiaMedica Therapeutics (NASDAQ:DMAC) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

DiaMedica Therapeutics currently has a consensus price target of $12.33, suggesting a potential upside of 97.33%. Olema Pharmaceuticals has a consensus price target of $44.40, suggesting a potential upside of 203.28%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than DiaMedica Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DiaMedica Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Olema Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.71

Olema Pharmaceuticals' return on equity of -42.95% beat DiaMedica Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
DiaMedica TherapeuticsN/A -77.72% -69.54%
Olema Pharmaceuticals N/A -42.95%-38.78%

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiaMedica TherapeuticsN/AN/A-$32.77M-$0.70N/A
Olema PharmaceuticalsN/AN/A-$162.45M-$1.86N/A

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by company insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Olema Pharmaceuticals had 4 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 6 mentions for Olema Pharmaceuticals and 2 mentions for DiaMedica Therapeutics. Olema Pharmaceuticals' average media sentiment score of 0.88 beat DiaMedica Therapeutics' score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DiaMedica Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Olema Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

DiaMedica Therapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500.

Summary

Olema Pharmaceuticals beats DiaMedica Therapeutics on 11 of the 13 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to uniQure?

uniQure (NASDAQ:QURE) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

DiaMedica Therapeutics has lower revenue, but higher earnings than uniQure. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
uniQure$16.10M82.90-$198.97M-$3.45N/A
DiaMedica TherapeuticsN/AN/A-$32.77M-$0.70N/A

78.8% of uniQure shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 4.8% of uniQure shares are held by insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

uniQure currently has a consensus price target of $44.50, suggesting a potential upside of 110.30%. DiaMedica Therapeutics has a consensus price target of $12.33, suggesting a potential upside of 97.33%. Given uniQure's higher possible upside, research analysts plainly believe uniQure is more favorable than DiaMedica Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
uniQure
1 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.53
DiaMedica Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

DiaMedica Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,236.00%. DiaMedica Therapeutics' return on equity of -77.72% beat uniQure's return on equity.

Company Net Margins Return on Equity Return on Assets
uniQure-1,236.00% -174.03% -27.41%
DiaMedica Therapeutics N/A -77.72%-69.54%

In the previous week, uniQure had 21 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 23 mentions for uniQure and 2 mentions for DiaMedica Therapeutics. uniQure's average media sentiment score of 0.59 beat DiaMedica Therapeutics' score of 0.00 indicating that uniQure is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
uniQure
6 Very Positive mention(s)
3 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
DiaMedica Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

uniQure has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.

Summary

uniQure beats DiaMedica Therapeutics on 8 of the 15 factors compared between the two stocks.

Get DiaMedica Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DMAC vs. The Competition

Export
MetricDiaMedica TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$336.77M$3.39B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-8.9338.8529.0428.47
Price / SalesN/A155.53476.6160.94
Price / CashN/A57.8827.6236.52
Price / Book5.797.039.676.67
Net Income-$32.77M$23.62M$3.55B$332.53M
7 Day Performance0.48%3.67%1.70%2.01%
1 Month Performance-3.55%7.16%5.62%9.20%
1 Year Performance56.25%67.03%34.42%39.59%

DiaMedica Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DMAC
DiaMedica Therapeutics
1.1032 of 5 stars		$6.25
+3.3%		$12.33
+97.3%		N/A$336.77MN/AN/A20
MPLT
Maplight Therapeutics
3.1645 of 5 stars		$30.70
-3.7%		$32.67
+6.4%		N/A$1.30BN/AN/A109
CRVS
Corvus Pharmaceuticals
3.2316 of 5 stars		$15.46
+1.8%		$33.33
+115.6%		N/A$1.30BN/AN/A30
GHRS
GH Research
2.214 of 5 stars		$20.71
+0.9%		$40.13
+93.7%		N/A$1.28BN/AN/A10
OLMA
Olema Pharmaceuticals
2.5347 of 5 stars		$14.32
-0.6%		$44.40
+210.1%		N/A$1.25BN/AN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DMAC) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel